As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Nature Medicine Open Access 04 September 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Griffith, M. et al. Nat. Genet. 49, 170–174 (2017).
Danos, A. M. et al. Genome Med. 11, 76 (2019).
Pleasance, E. et al. Nat. Cancer 1, 452–468 (2020).
Madhavan, S. et al. Pac. Symp. Biocomput. 23, 247–258 (2018).
Wagner, A. H. et al. Nat. Genet. 52, 448–457 (2020).
Zhou, X. et al. Nat. Genet. 48, 4–6 (2016).
Pratt, D. et al. Cancer Res. 77, e58–e61 (2017).
Pagel, K. A. et al. JCO Clin. Cancer Inform. 4, 310–317 (2020).
Pawliczek, P. et al. Hum. Mutat. 39, 1690–1701 (2018).
Nielsen, S. M. et al. J. Clin. Oncol. 34, 2172–2181 (2016).
Li, M. M. et al. J. Mol. Diagn. 19, 4–23 (2017).
Danos, A. M. et al. Hum. Mutat. 39, 1721–1732 (2018).
Richards, S. et al. Genet. Med. 17, 405–424 (2015).
Köhler, S. et al. Nucleic Acids Res. 49, D1207–D1217 (2021).
Horak, P. et al. Genet. Med. 24, 986–998 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
E.K.B. is an owner, employee and member of Geneoscopy, and an inventor of the intellectual property owned by Geneoscopy. K.M.C. is a shareholder in Geneoscopy and has received honoraria from PACT Pharma and Tango Therapeutics. D.T.R. provides consulting for Alacris Theranostics and has received honoraria from Bayer, Eli Lilly and Bristol Myers Squibb.
Rights and permissions
About this article
Cite this article
Krysiak, K., Danos, A.M., Kiwala, S. et al. A community approach to the cancer-variant-interpretation bottleneck. Nat Cancer 3, 522–525 (2022). https://doi.org/10.1038/s43018-022-00379-w
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-022-00379-w
This article is cited by
-
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Nature Medicine (2025)
